UCB (OTCMKTS:UCBJY) Share Price Crosses Above 50 Day Moving Average – What’s Next?

UCB SA (OTCMKTS:UCBJY)’s share price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $143.16 and traded as high as $147.94. UCB shares last traded at $146.91, with a volume of 25,401 shares changing hands.

Analysts Set New Price Targets

A number of research firms recently issued reports on UCBJY. Zacks Research downgraded shares of UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 11th. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research report on Monday, June 22nd. Finally, Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

UCB Trading Down 2.0%

The company has a 50 day moving average of $143.16 and a two-hundred day moving average of $147.77. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.